Why Attend the Cell & Gene Therapy Pricing & Reimbursement Summit?

The 3rd Cell & Gene Therapy Pricing & Reimbursement Summit puts you inside the real forward-looking conversations shaping cell and gene therapy market access today and for the future. Across high impact case studies, payer led discussions, policy deep dives, and action focused sessions, you’ll uncover exactly how to drive payer and treatment centre engagement, secure coverage, remove access barriers, and drive stronger commercial uptake. With hard won lessons from newly approved therapies and guidance from top market access leaders, this meeting gives you the playbook, clarity, and competitive edge needed to navigate a complex landscape for cell and gene therapy pricing, reimbursement, and patient access.

16 (3)

What to Expect?

Build a High Confidence Strategy from Launch to Year One

Learn from Neurotech Pharmaceuticals’ first year commercial experience to understand how they built payer confidence prelaunch, aligned pricing with value expectations, and supported diverse practice settings through financial pathways that reduced provider risk and accelerated early Medicare claims.

Feed Your Curiosity About the Cell & Gene Therapy Access Model in Practice

Learn directly from Genetix Biotherapeutics’ experience with the Cell and Gene Therapy Access Model to understand how early payer engagement, outcomes aligned contracting, and evidence generation accelerated patient adoption, and what manufacturers must provide to strengthen coverage pathways.

Understand How Commercial & Employer Plans Evaluate Cell & Gene Therapies

Go behind the scenes with Blue Cross Blue Shield and the Partnership for Employer-Sponsored Coverage to understand how carveouts, reinsurance structures, and affordability thresholds influence whether patients gain access, and at what speed.

Gain Insight into Treatment Center Readiness & Real-World Delivery

Understand the operational and financial realities treatment centres face with OneOncology, and hear more about Kite Pharma and Bristol Myers Squibb’s experiences with expanding their network treatment centres into the community oncology setting.

Explore the Full Event Guide

  • 20+ speakers from leading cell and gene manufacturers, healthcare providers, commercial and government payers, and policy experts
  • Network with 80+ like-minded professionals focused on addressing the latest policy and commercialization challenges for cell and gene therapies
  • Hear case studies from involvement with the Cell and Gene Therapy Access Model, and the latest on launching a product in 2026
  • The only meeting exclusively dedicated to market access, pricing, and reimbursement challenges for cell and gene therapies
ee7 brochure image (4) (1)

Attending Companies Include

14 (3)

Explore the Agenda

Dive into the only agenda that unpacks real world cell and gene therapy pricing, reimbursement, evidence generation, payer strategy, and policy shifts shaping market viability today.

12 (2)

Partner With Us

Position your solutions at the center of cell and gene therapy market access, payer engagement, and commercialization strategy conversations attended by the field’s leading decisionmakers.

22 (1)

Join Biopharma Experts

Network with the manufacturers, payers, policy leaders, and access strategists defining the future of cell and gene therapy coverage, affordability, and sustainable patient access.